A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors

Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer

(2011) Richard Kim et al.   CANCER

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

(2011) Auke D. Adema et al.   INVESTIGATIONAL NEW DRUGS

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

(2010) Andries M. Bergman et al.   INVESTIGATIONAL NEW DRUGS

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer

(2009) A. Adema et al.   CURRENT MEDICINAL CHEMISTRY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer

(2008) James J. Farrell et al.   GASTROENTEROLOGY

Sequential design approaches for bioequivalence studies with crossover designs

(2007) Diane Potvin et al.   PHARMACEUTICAL STATISTICS